How Mikhail Blagosklonny has Played a Major Role in Oncology and Cancer Research

Mikhail Blagosklonny is one of the renowned scientists in oncology and cancer research. Currently, he works as the professor of oncology at the popular Roswell Park Cancer Institute situated in New York. Mikhail’s research touches on various interests including cellular and molecular biology, as well as clinical investigations.

On a more specific level, Mikhail Blagosklonny specializes on cell cycle, signal transduction, tumor suppressors, anticancer therapeutics, mitosis and apoptosis. His research also extends to aging and other age-related illnesses. In this case, Mikhail looks at the underlying aspects or mechanism of aging.

Academic and Career Background

Blagosklonny backs up his roles as a professor and scientist with excellent academic records. He not only has an M.D in internal medicine but also holds a Ph.D. in cardiology and experimental medicine. Mikhail earned his Ph.D. from the First Pavlov State Medical University of St. Petersburg.

Mikhail embarked on his career in 2002 at the New York Medical College where he served in the capacity of an appointed associate professor. He then took up a position at Albany-based Ordway Research Institute as a senior scientist. Blagosklonny ended his tenure at Ordway Research after being appointed as the professor of oncology at the Roswell Park Cancer Institute.

Blogosklonny’s Hypothesis

In his research work, Blagosklonny is acknowledged for formulating a hypothesis regarding the possible function of TOR signaling in cancer and aging. Consequently, he suggested the use of a popular cancer treatment drug, rapamycin, as a possible cure for life extension. For this reason, he is considered by many as one of the enthusiastic proponents of using rapamycin in life extension research.

Read more: https://templeofthecave.com/mikhail-blagosklonny-a-review-of-his-life-achievements/

Editorial Work

As an author, Blagosklonny is known for coining with the hyper-function theory of aging and anti-cancer approaches called cyclotherapy and chemotherapeutic engineering. Over the years, he has taken part in the publication of about 300 research reviews, articles and book chapters. Mikhail Blagosklonny is the editor-in-chief and founding editor of Cell Cycle. He is also the co-founder and co-editor of Aging, Oncotarget and Oncoscience. Additionally, he serves as an associate editor of Cancer Biology & Therapy, International Journal of Cancer, PLOS ONE and Autophagy, Cancer Research, Cell Death and Differentiation. View Mikhail’s profile on Google Scholar